Table 3.
DCE respondent characteristics
| Characteristic no. (%) | Respondents (n = 116) |
|---|---|
| Gender | |
| Females | 62 (53%) |
| Males | 53 (46%) |
| Not reported | 1 (1%) |
| Age, years Median age 60, range 26–82 | |
| 15–24 | 0 (0%) |
| 25–44 | 16 (14%) |
| 45–64 | 59 (51%) |
| 65–74 | 34 (29%) |
| 75+ | 6 (5%) |
| Not reported | 1 (1%) |
| Children | |
| Yes | 93 (80%) |
| No | 22 (19%) |
| Not reported | 1 (1%) |
| Highest education level | |
| High school only/diploma/TAFE | 62 (53%) |
| University degree | 52 (45%) |
| Not reported | 2 (2%) |
| Annual pre-tax household income | |
| ≤ AU$87,999 | 37 (32%) |
| ≥ AU$88,000 | 64 (55%) |
| Prefer not to answer/income not reported | 15 (13%) |
| Health insurance status | |
| Private health insurance | 79 (68%) |
| Healthcare concession/Department Veterans’ Affairs/Medicare only | 35 (30%) |
| Not reported | 2 (2%) |
| Stage of disease (AJCC 8th Edition) | |
| IIIA | 24 (21%) |
| IIIB | 29 (25%) |
| IIIC | 27 (23%) |
| IIID | 3 (3%) |
| Stage III sub-stage not known | 33 (28%) |
| Treated with immunotherapy | 92 (79%) |
| Duration of immunotherapy in months, median (range) | 4 (1 to > 12) |
| Respondents ceased immunotherapy because of toxicity | 17–92 (19%) |
| Melanoma treatment | |
| Surgical resection plus other treatments, including adjuvant immunotherapy | 91 (79%) |
| Surgical resection only | 15 (13%) |
| Surgical resection plus other treatments, excluding adjuvant immunotherapy | 8 (6%) |
| Not reported | 2 (2%) |
AU Australian